SAN FRANCISCO , May 08, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations. “We are living in unprecedented times as the impact of the COVID-19
Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the growing unmet need in diseases caused by transthyretin amyloidosis, or ATTR. ATTR is caused by the destabilization of TTR due to inherited mutations or aging and is commonly divided into 3 distinct categories: wild-type ATTR cardiomyopathy (wtATTR-CM), variant ATTR ...